Idexx Laboratories
IDXX
1,032 hedge funds and large institutions have $46.1B invested in Idexx Laboratories in 2021 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 332 increasing their positions, 382 reducing their positions, and 72 closing their positions.
56% more funds holding in top 10
Funds holding in top 10: 25 → 39 (+14)
47% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 72
30% more capital invested
Capital invested by funds: $35.6B → $46.1B (+$10.5B)
2% more funds holding
Funds holding: 1,011 → 1,032 (+21)
0.52% more ownership
Funds ownership: 85.26% → 85.79% (+0.52%)
13% less repeat investments, than reductions
Existing positions increased: 332 | Existing positions reduced: 382
37% less call options, than puts
Call options by funds: $147M | Put options by funds: $232M
Top Buyers
| 1 |
BlackRock
New York
|
+$242M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$123M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$88.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$74.2M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$68.9M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$300M |
| 2 |
BAMCO Inc
New York
|
-$118M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$64.5M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$62.5M |
| 5 |
Millennium Management
New York
|
-$50.5M |
IDXX Hedge Fund Activity: Q2 2021 in Review
1,032 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Idexx Laboratories (IDXX) for Q2 2021, worth a combined $46.1B — up 30% from $35.6B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new IDXX positions and 72 closed out — a net gain of 34 holders — while 332 added to existing stakes and 382 trimmed.
The largest buyer was BlackRock, adding an estimated $242M. The largest seller was T. Rowe Price Associates, cutting an estimated $300M.
- 1,032 institutional investors held Idexx Laboratories (IDXX) as of Q2 2021, up from 1,011 in Q1 2021.
- Funds reported $46.1B of Idexx Laboratories stock for Q2 2021, up 30% quarter-over-quarter.
- 106 funds opened new Idexx Laboratories positions in Q2 2021 and 72 closed out, a net change of +34 holders.
- The largest Idexx Laboratories buyer in Q2 2021 was BlackRock, an estimated $242M added.
- The largest Idexx Laboratories seller in Q2 2021 was T. Rowe Price Associates, an estimated $300M sold.
Based on aggregated 13F filings for Q2 2021.